The impact of acute lymphoblastic leukemia treatment on central nervous system results in Bogota, Colombia
| dc.creator | H, Maria Teresa Amparo Buendia | |
| dc.creator | Lozano, Juan Manuel | |
| dc.creator | Suarez, Gloria Elena | |
| dc.creator | A, Carlos Saavedra | |
| dc.creator | Guevara, Gonzalo | |
| dc.date | 2008 | |
| dc.date | 2020-05-25T23:56:25Z | |
| dc.date.accessioned | 2023-11-21T15:55:44Z | |
| dc.date.available | 2023-11-21T15:55:44Z | |
| dc.description | To improve the outcome of children with acute lymphoblastic leukemia (ALL) treated at the National Cancer Institute, Bogota, Colombia, a protocol based on the BFM-90 (Berlin, Frankfurt, Munster study) and the LSA2L 2 regimens was implemented in the year 1993. The patients were classified as being standard risk (SR) or high risk (HR) according to clinical criteria, to which cytogenetic information and day-8 prednisone response were also added. A 123-patient cohort entered the study, 18 of them being considered SR and 105 HR. There was a 94% 10 years' event-free-survival rate for the SR group and 36% for the HR group. Decreased induction death rate (7% vs. 14%), increased complete remission (CR) rate (81% vs. 75%), and continuous CR (45% vs. 33%) were found in comparison with the previous study. A significant improvement was achieved in relapse rate, 44% to 28% (P=0.029), mainly due to reduced central nervous system relapse rate from 16% to 6% (P=0.037), whereas the number of patients receiving cranial radiation was reduced to 55%. A major problem concerned the increased CR mortality rate, 5% to 14% (P=0.06). Improved supportive care therapy and socioeconomic conditions will hopefully reduce the CR mortality rate in the future. © 2008 by Lippincott Williams and amp; Wilkins. | |
| dc.format | application/pdf | |
| dc.identifier | https://doi.org/10.1097/MPH.0b013e31817e4a7d | |
| dc.identifier | 10774114 | |
| dc.identifier | 15363678 | |
| dc.identifier | https://repository.urosario.edu.co/handle/10336/22419 | |
| dc.identifier.uri | http://repository-salesiana.heoq.net/handle/123456789/268047 | |
| dc.language | eng | |
| dc.publisher | Lippincott Williams and Wilkins | |
| dc.relation | https://www.scopus.com/inward/record.uri?eid=2-s2.0-66249140940&doi=10.1097%2fMPH.0b013e31817e4a7d&partnerID=40&md5=e598420d36c5852e7b9e3e3437f5b342 | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.source | instname:Universidad del Rosario | |
| dc.source | reponame:Repositorio Institucional EdocUR | |
| dc.subject | Antineoplastic agent | |
| dc.subject | Asparaginase | |
| dc.subject | Cyclophosphamide | |
| dc.subject | Cytarabine | |
| dc.subject | Daunorubicin | |
| dc.subject | Dexamethasone | |
| dc.subject | Doxorubicin | |
| dc.subject | Folinate calcium | |
| dc.subject | Mercaptopurine | |
| dc.subject | Methotrexate | |
| dc.subject | Prednisone | |
| dc.subject | Acute lymphoblastic leukemia | |
| dc.subject | Adolescent | |
| dc.subject | Article | |
| dc.subject | Cancer chemotherapy | |
| dc.subject | Cancer mortality | |
| dc.subject | Cancer radiotherapy | |
| dc.subject | Cancer regression | |
| dc.subject | Cancer relapse | |
| dc.subject | Cancer risk | |
| dc.subject | Cancer survival | |
| dc.subject | Central nervous system | |
| dc.subject | Child | |
| dc.subject | Colombia | |
| dc.subject | Controlled study | |
| dc.subject | Cytogenetics | |
| dc.subject | Drug dose reduction | |
| dc.subject | Drug megadose | |
| dc.subject | Female | |
| dc.subject | Human | |
| dc.subject | Infant | |
| dc.subject | Major clinical study | |
| dc.subject | Male | |
| dc.subject | Multiple cycle treatment | |
| dc.subject | Preschool child | |
| dc.subject | Priority journal | |
| dc.subject | School child | |
| dc.subject | Treatment outcome | |
| dc.subject | Treatment response | |
| dc.subject | Adolescent | |
| dc.subject | Antineoplastic combined chemotherapy protocols | |
| dc.subject | Central nervous system neoplasms | |
| dc.subject | Child | |
| dc.subject | Cohort studies | |
| dc.subject | Colombia | |
| dc.subject | Cranial irradiation | |
| dc.subject | Cytogenetic analysis | |
| dc.subject | Humans | |
| dc.subject | Infant | |
| dc.subject | Precursor cell lymphoblastic leukemia-lymphoma | |
| dc.subject | Prednisone | |
| dc.subject | Recurrence | |
| dc.subject | Remission induction | |
| dc.subject | Risk | |
| dc.subject | Survival rate | |
| dc.subject | Cns-leukemia | |
| dc.subject | Developing country | |
| dc.subject | Intensive chemotherapy | |
| dc.subject | Pediatric all | |
| dc.subject | preschool | |
| dc.subject | Child | |
| dc.title | The impact of acute lymphoblastic leukemia treatment on central nervous system results in Bogota, Colombia | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/publishedVersion |